Journal of the American Academy of Dermatology
Volume 56, Issue 1 , Pages e55-e79, January 2007

Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2)

  • Julia E. Graves, MD

      Affiliations

    • From the Divisions of Dermatology, Washington University, St Louis
  • ,
  • Kara Nunley, MD

      Affiliations

    • From the Divisions of Dermatology, Washington University, St Louis
  • ,
  • Michael P. Heffernan, MD

      Affiliations

    • Wright State University School of Medicine, Dayton
    • Corresponding Author InformationReprint requests: Michael P. Heffernan, MD, Chief, Division of Dermatology; Associate Professor of Dermatology, Wright State University School of Medicine, One Elizabeth Place, Suite 200, Dayton, OH 45408-1445.

published online 10 November 2006.

St Louis, Missouri, and Dayton, Ohio

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Funding sources: None.Disclosure: Dr Heffernan has been a paid investigator, lecturer and/or consultant for Abbott, Amgen, Biogen-IDEC, Centocor and Genentech. Drs Heffernan and Graves have been active in industry-sponsored research.Presented at the 63rd Annual Meeting of the American Academy of Dermatology, New Orleans, Louisianna, February 18-22, 2005.

PII: S0190-9622(06)02085-8

doi:10.1016/j.jaad.2006.07.019

Journal of the American Academy of Dermatology
Volume 56, Issue 1 , Pages e55-e79, January 2007